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The objective of this study was to determine specific combination of pharmaceutical excipients that lead 
to formulation of efficient nebivolol hydrochloride SMEDDS and its subsequent formulation into IR-SET 
(Immediate release- Self emulsifying tablet) which will enhance its solubility and dissolution. Solubility 
and Pseudo-ternary phase studies were carried out to identify the excipients showing highest solubility 
and to identify the zone of microemulsion with selected ingredients. Liquid-SMEDDS (L-SMEDDS) were 
optimized for Concentration of oil(X1) and Smix(X2) and formulated using a combination of Kollisolv 
GTA as oil, Tween 80 as surfactant and propylene glycol as co-surfactant which gave smaller droplet 
size(Y1) 55.98nm , Emulsification time (Y2) 16±1.5 s,% transmittance (Y3) 99.94±0.47%. Neusilin 
US2 was used as solid carrier for solidification of L-SMEDDS in to Solid-SMEDDS (S-SMEDDS) by 
adsorption technique. IR-SET of nebivolol were formulated with S-SMEDDS and optimized for the 
concentration of binder (X1) (PVP K30) and superdisintegrant (X2) (KOLLIDON CL) which showed low 
Disintegration time (Y1) (92±0.5s) and low Friability(Y2)(0.424±0.03%). Also the DSC and XRD data 
revealed the molecular state of the drug in S-SMEDDS. The extent of in-vivo drug release and ex-vivo 
diffusion values from L-SMEDDS and IR-SET was much higher than pure drug and marketed tablet. In 
conclusion, the results showed potential of SMEDDS to improve solubility and thus the bioavailability.
Keywords: Nebivolol hydrochloride. Liquid & Solid SMEDDS. Full factorial design. Neusilin US2 
IR-SET.
INTRODUCTION
Nebivolol HCl (NEB) is an oral, highly selective 
third generation β1-receptor antagonist, having nitric 
oxide enhancing vasodilator effect, indicated for the 
treatment of hypertension. NEB is the newer drug 
among those β1-Adrenergic blockers and also used as 
monotherapy for initial management of uncomplicated 
hypertension (Thadkala, Sailu, Aukunuru, 2015). Also 
NEB has reduced typical beta-blocker related side effects 
such as fatigue, clinical depression, bradycardia, and 
impotence (Narkhede, Gujar, Gambhire, 2014). After oral 
administration of NEB, the peak plasma concentration 
reaches within 0.5-2 h. Oral bioavailability of NEB is 12% 
only because of first pass hepatic metabolism caused by 
cytochrome P450 2D6 (CYP2D6) enzymes. It has suitable 
log P (octanol/water) of 4.03 and the recommended daily 
dose is 5 mg (Vijayanand, Patil, Reddy, 2015).The drug 
is highly lipophilic belonging to the class BCS II, having 
low dissolution velocity and bioavailability (Narkhede, 
Gujar, Gambhire, 2014). The bioavailability can be 
increased by increasing its solubility and reducing first 
pass metabolism. Studies have shown that the solubility 
and stability of lipophilic compounds can be increased by 
incorporating them into microemulsion based delivery 
systems due to their small droplet size and kinetic stability 
(Jaiswal et al., 2014).
S e l f - m i c r o e m u l s i f y i n g  d r u g  d e l i v e r y 
systems(SMEDDS), one among the lipid-based dosage 
forms are proven to be promising in improving the 
oral bioavailability of drug by enhancing solubility, 
permeability and avoiding first-pass metabolism via 
enhanced lymphatic transport (Mahajan et al., 2011). 
SMEDDS are contemplated as isotropic mixtures of a 
drug, oil, surfactant, and a cosurfactant (Gurram et al., 
H. R. Trivedi, T. M. Siriah, P. K. Puranik
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2015). The fundamental basis of a SMEDDS system 
lies in its potential of forming oil-in-water (o/w) micro-
emulsions with slight agitation and dilution with aqueous 
phases. The impromptu formation of this micro-emulsion 
in the gastrointestinal tract dispenses the drug in a more 
solubilized form, and a large surface area is provided by 
the small size of the formed droplet for drug absorption. 
Moreover there is increase in bioavailability due to the 
presence of lipid in the formulation (Narkhede, Gujar, 
Gambhire, 2014). 
Various efforts have been made to develop effective 
delivery systems to improve water solubility and 
bioavailability of NEB including preparation of liquidsoid 
compact (Pravala, Nagabandi, Ajmeera, 2013), solid 
dispersions (Shah, Bhatt, Yadav, 2014), nanoparticulate 
delivery (Jana et al., 2014), oral nanoemulsion (Thadkala, 
Sailu, Aukunuru, 2015), orodispersible (Vijayanand, Patil, 
Reddy, 2015) and immediate release tablets (Khalaf et al., 
2015).
Self-emulsification has been shown to be specific 
to the nature of the oil/surfactant pair; the surfactant 
concentration and oil/surfactant ratio; and the temperature 
at which self-emulsification occurs. Only very specific 
pharmaceutical excipients combinations lead to efficient 
self-emulsifying systems (Rahman et al., 2013; Zanchetta, 
Chaud, Santana, 2015). However, scanty work is reported 
on the use of different oil/surfactant/co-surfactant and 
adsorbent in the preparation of NEB SMEDDS and its 
subsequent design in immediate release tablet formulation. 
Hence, in the present study an attempt was made toward 
the use of different oils, surfactants and co-surfactants 
for the preparation of L-SMEDDS and use of different 
adsorbents for preparing solid SMEDDS, IR-SET and 
their optimization and evaluation.
MATERIAL AND METHODS
Material
NEB was procured as a gift sample from Emcure 
Pharmaceutical Ltd. Pune. Kollisolv GTA(Triacetin), 
Kollisolv IPM(Isopropyl myristate), MCT 70(Medium 
chain triglyceride),  Solutol HS 15(Polyoxyl 15 
hydroxystearate), KOLLIDON CL (Polyvinylpyrrolidone 
crosslinked) were provided by BASF, Mumbai as a gift 
sample. Acrysol EL 135(Polyoxyl 35- hydrogenated castor 
oil) and Acrysol K 140(Polyoxyl 40- hydrogenated castor 
oil) were kindly gifted by Corel Pharma Ltd. Ahemdabad. 
Neusilin US2 (Magnesium aluminum silicate) was 
acquired as a gift sample from Fuji Chemicals, Japan. 
While Aerosil 200 (Silicon dioxide) was gifted by Evonik 




Melting point of NEB was determined using Thiele 
tube method (Furniss et al., 2008). The analytical method 
development was done using UV spectroscopic analysis. 
Calibration plot of NEB was performed in methanol, 
hydrochloric acid buffer pH 1.2 and phosphate buffer 
pH 7.4 (PBS). A standard stock solution of 100 μg/mL 
was prepared, and from this different concentrations 
in the range of 20-100 μg/mL solution were prepared 
and used to determine the λmax and calibration curves 
(Thula, Patel, Maheshwari, 2015). Various validation 
parameters like linearity, interday precision, intraday 
precision, robustness, ruggedness, limit of detection, 
limit of quantitation and% recovery/accuracy study 
were determined in accordance with the ICH guidelines 
(Thula, Patel, Maheshwari, 2015).Characterization 
of NEB was done by obtaining FT-IR spectra using 
Shimadzu–IRAFFINITY–1 FT-IR spectrophotometer. 
The thermal behaviour of the drug was evaluated using 
differential scanning calorimeter and the enthalpy and 
melting point range was determined (Vijayanand, Patil, 
Reddy, 2015).
Solubility studies - selection of SMEDDS 
components 
Selection of oil 
Solubility of NEB was checked in different oils, 
surfactants and cosurfactants. 2 mL of various oils, 
surfactants, and co-surfactants were taken individually 
in small vial and surplus drug (100 mg) was added to 
each vial. The vials were tightly sealed and then heated at 
40 oC in water bath for further solubilisation (Vijayanand, 
Patil, Reddy, 2015). The mixtures were then sonicated for 
15 minutes and stirred steadily for 72 h with mechanical 
shaker for proper mixing. Once the mixtures reached 
equilibrium the contents of all vials were centrifuged 
at 10,000 rpm for 30 minutes (Remi C-24 plus, India). 
Aliquot of sample was taken and diluted with methanol 
at specific volume to give specific point concentration in 
calibration curve. Analysis of the drug was carried out on 
double beam UV-Visible spectrophotometer at 650nm by 
placing a blank. The quantification was done according to 
calibration curve and column graphs were plotted taking 
solubility in mg per mL as ordinate axis (Prajapati, Joshi, 
Patel, 2013). 
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Selection of surfactant
The criteria for selecting surfactant depended on 
its ability to emulsify the selected oil phase. To evaluate 
the emulsification ability, surfactant was added to the 
selected oil phase, blended thoroughly and then this 
mixture was diluted with distilled water. The ease of 
formation of emulsion was monitored by the number 
inversions of volumetric flask required to produce uniform 
emulsion. The emulsion was allowed to stand for 2 h and 
its transmittance was measured. Emulsion was further 
monitored for any turbidity or phase separation (Prajapati, 
Joshi, Patel, 2013).
Selection of co-surfactant
Co-surfactants were assessed for their influence 
over the selected surfactants, so as to improve the 
emulsification capability of the surfactants. For which, a 
mixture of surfactant and co-surfactant was prepared at a 
ratio of 2:1. To this mixture was added the oil phase and 
then gently heated in a water bath for proper mixing. This 
mixture was then diluted with distilled water and observed 
for the number of inversions required to produce uniform 
emulsion. Transmittance was measured after the emulsion 
was allowed to stand for 2 h (Prajapati, Joshi, Patel, 2013).
Drug excipients compatibility studies
FTIR Studies
FTIR – 8001 spectrophotometer (Shimadzu, Japan) 
was used to obtain spectra of NEB in the isotropic mixtures 
of excipients. Analysis of pure NEB, NEB with Kollisolv 
GTA, Tween 80 and Propylene glycol (L-SMEDDS) & 
SMEDDS loaded Neusilin US2, Avicel PH102, PVP K30, 
KOLLIDON CL (IR-SET) were recorded by KBR pellet 
method. The spectrum was recorded over the frequency 
range of 4000 to 400 cm−1 and screened for appearance or 
disappearance of any peak (Patela et al., 2010).
DSC studies
DSC thermograph of pure NEB, NEB with Kollisolv 
GTA, Tween 80 and Propylene glycol (L-SMEDDS) & 
SMEDDS loaded Neusilin US2, Avicel PH102, PVP K30, 
KOLLIDON CL (IR-SET) were recorded on differential 
scanning calorimeter. Thermograms were matched for 
appearance or disappearance of any peak (Patela et al., 
2010). 
Pseudo-ternary phase diagram
Pseudo-ternary phase diagrams were plotted for 
the excipients selected from solubility and emulsification 
studies to evaluate the boundaries of the micro emulsion 
domains. Water titration method was used to plot pseudo-
ternary phase diagram of oil, Smix (surfactant/co-
surfactant mixture) and doubled distilled water. Various 
weight ratios of Smix were selected as 1:1, 1:2, 2:1, 1:3 and 
3:1. For all pseudo-ternary phase plots, at a specific Smix 
weight ratio, the mixtures of oil-surfactant-cosurfactant 
were prepared with the weight ratio of oil to the Smix at 
9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 respectively. To 
the resultant mixtures, water was added drop wise along 
with proper stirring, the first sign of clarity in mixture 
indicate the end point. The point indicating the clear and 
isotropic mixtures were considered to be within the micro 
emulsion. The pseudo-ternary phase plots were then 
constructed by monitoring the mixtures visually, using a 
software - CHEMIX. The ratio of Smix showing largest 
micro emulsion zone was selected. Moreover, to analyze 
the effects of NEB on the emulsifying performance of 
SMEDDS, the formulation quantity of NEB was added to 
the boundary formulations of the self-emulsifying domain 
of the pseudo-ternary phase plots (Rao et al., 2013). 
Formulation and optimization of NEB loaded 
L-SMEDDS by experimental design
A 32 full factorial design measures the response of 
every possible combination of factors and factor levels 
and thus suitable for optimizing SMEDDS. It analyzes 
every response to provide information about main effect 
and interaction effect. NEB loaded L-SMEDDS were 
formulated by adding the weighed amount of oil into a 
screw-capped glass vial and melting it at 40 °C water 
bath. To this mixture, surfactant and co-surfactant were 
added and stirred with a magnetic stirrer. The mixture was 
then further sonicated for 15 minutes and stored at room 
temperature until their use in subsequent studies. Based on 
the data available from the pseudo-ternary phase diagram, 
two independent variables, namely the concentration 
of oil(X1) as well as the concentration of the Smix(X2) 
were recognized as important factors responsible for the 
characteristics of L-SMEDDS, while the droplet size (Y1), 
emulsification time (Y2) and percent transmittance (Y3) 
were selected as dependent variables for obtaining the 
optimized liquid SMEDDS as shown in Table I. A total 
of 9 batches were prepared and evaluated for droplet size, 
emulsification time and percent transmittance. 
This data was statistically analyzed and validated by 
Design Expert (Version 8.0.0, Stat-Ease Inc., Minneapolis, 
MN). ANOVA tables were generated and P-values less 
than 0.05 were considered to be statistically significant. 
Various 3-D response surface graphs and contour 
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plots were studied for understanding the effect of both 
formulation variables (Pimple, Yeole, Chaudhari, 2013).
The polynomial equation was obtained for droplet size, 
emulsification time and percent transmittance time using 
Design Expert software.
Y=b0+b1 X1+b2 X2+b12 X1X2+b11X12+b22X22
where Y is dependent variable, b0 is the arithmetic 
mean response of the nine runs and bi(b1- b22) is the 
approximate coefficient for the correlated factor Xi 
(X1-X22).The interaction term (X1X2) shows the changes 
in the response when two factors are concurrently changed 
and the polynomial terms (X12 and X22) are incorporated 
to determine nonlinearity. The validity of the developed 
polynomial equation was verified using design check 
point analysis.
Evaluation of L-SMEDDS
Self emulsification time analysis and percent 
transmittance
USP dissolution apparatus II was used to determine 
the emulsification time of SMEDDS. For this, 1 mL 
of formulation was added in a drop wise manner at 
37 ± 0.5 °C to 500 mL of distilled water. Slight agitation 
was supplied by dissolution paddle rotating at 50 rpm. 
Time required for emulsification time was observed 
visually (Khan et al., 2012). Further the sample was 
subjected to percent transmittance analysis using double 
beam UV-Visible spectrophotometer using distilled water 
as blank at wavelength of 650 nm (Rao et al., 2013).
Droplet size analysis and Zeta potential determination
Photon correlation spectroscopy using NANOPHOX 
(NX0088) was employed to determine the droplet size 
of the prepared formulation. Mean droplet size and 
polydispersity index was determined by diluting 1 mL of 
formulation with double distilled water (Rao et al., 2013). 
Similarly zeta potential of the prepared formulation was 
determined by Malvern Zetasizer 3000HS (Pandey, Kohli, 
2017).
Drug loading capacity 
Drug loading capacity of SMEDDS mixture was 
determined by taking 2 mL of optimized SMEDDS in 
small vial with excess amount of the drug (100 mg). The 
vial was tightly sealed and for further solubilization, the 
mixture was heated in water bath at 40 °C. Mixing of the 
system was performed using sonicator for 15 minutes 
and was stirred continuously for 72 h using mechanical 
shaker. After reaching equilibrium, the content of vial 
was centrifuged at 10,000 rpm for 30 minutes. Aliquot of 
sample was taken and diluted with methanol to specific 
volume to give specific point concentration in calibration 
curve (Akhildevi et al., 2016). 
Cloud point determination
The temperature at which there is appearance of 
cloudiness in the formulation is called as cloud point. For 
cloud point determination the formulation was diluted 
with distilled water in the ratio of 1:250 and then placed 
in a water bath with the temperature gradually increasing 
at 2 °C intervals (Pandey, Kohli, 2017). 
Phase separation study
SMEDDS were diluted to 50, 100, and 1,000 times 
with various dissolution media, i.e., water, acid buffer 
pH 1.2 and phosphate saline buffer pH 7.4. The diluted 
micro emulsions were stored for 12 h and monitored 
visually for any signs of phase separation or drug 
precipitation (Rao et al., 2013).
TABLE I - Dependent and independent variables in experimental design used for optimization of L-SMEDDS & IR-SET
Formulation Types of variable Variable Optimization levels used
Low (-1) Medium (0) High (+1)
L-SMEDDS Independent X1 (Concentration of Oil) 







Dependent Y1 (Droplet size) 
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Thermodynamic stability 
Physical stability is crucial for efficiency of a lipid 
based formulation. Thermodynamic stability studies 
consist of three phases. Phase I is the heating and cooling 
cycle where formulation undergoes six heating and cooling 
cycles, carried out at temperature 40 °C and 4 °C and stored 
for not less than 48 h at each temperature. After completion 
of the cycle, the formulation is centrifuged (Phase II) at 
5000 rpm for a period of 30 minutes. It was then checked 
for any physical instability like phase separation, creaming 
or cracking. Formulation which passed Phase I and II is 
then subjected to 3 freeze-thaw cycles (Phase III), which 
comprised of freezing the formulation at −4 °C for 48 h 
followed by thawing it at 40 °C for 48 h. Formulation 
passing these entire three tests is considered as stable 
formulation (Rao et al., 2013).
Drug content
The drug content of L-SMEDDS formulation was 
determined by placing SMEDDS equivalent to dose of 
drug in 10 mL volumetric flask and diluted with methanol. 
The flask was then subjected to sonication for 30 minutes. 
Necessary dilution was made with methanol. The solution 
was then filtered through whatman filter paper and 
analyzed spectrophotometrically (Rao et al., 2013).
Preparation of Solid NEB SMEDDS
Solid NEB SMEDDS were prepared by mixing 
L-SMEDDS containing NEB with adsorbent in particular 
proportion. In brief L-SMEDDS were added drop wise 
over adsorbent contained in small mortar. After each 
addition, mixture was homogenized using pestle to 
ensure uniform distribution of formulation. The obtained 
damp mass was then passed through sieve and air dried at 
ambient temperature and stored until further use.
Selection of adsorbent for S-SMEDDS 
S-SMEDDS of individual adsorbent like Neusilin 
US2, Aerosil 200, microcrystalline cellulose PH102 and 
lactose were prepared by adsorption onto carrier technique. 
The prepared S-SMEDDS were further evaluated for flow 
properties, compressibility index and characterized by 
Scanning electron microscopy and X-ray diffraction study 
(Laddha, Suthar, Butani, 2014).
Formulation of immediate release self emulsifying 
tablet (IR-SET)
Selection of super-disintegrant 
In order to achieve IR-SET of NEB, super-
disintegrants like Croscarmellose sodium, Sodium starch 
glycolate and KOLLIDON CL were studied by preparing 
their preliminary batches. The disintegration time was 
observed as a response.
Formulation and optimization of NEB IR-SET using 
factorial design 
IR-SET of  NEB was formulated by direct 
compression technique. For this, NEB containing 
S-SMEDDS and other excipients were accurately weighed, 
passed through sieve 22 and blended for 15 minutes. To 
this blend was added magnesium stearate which was 
previously passed through sieve 60. This mixture was then 
compressed into tablets weighing 450 mg using 10 station 
rotary tablet compression machine with 10.0 mm flat 
round punches (Chamunda Pharma Machinery Pvt. Ltd. 
Ahmedabad) (Ahammad, Pani, 2016).
A 32 full factorial design was selected to study the 
effect of the independent variables i.e. Concentration of 
PVP K30 (X1) and Concentration of KOLLIDON CL 
(X2) on the dependent variables - Disintegration time and 
Friability. The approximate levels of these independent 
variables were chosen from results of preliminary batches 
and are given in Table I. Statistical analysis was carried 
out for the obtained data, and was further validated by 
Design Expert (Version 8.0.0, Stat-Ease Inc., Minneapolis, 
MN). Various 3-D response surface graphs and contour 
plots were studied to study the effect of the formulation 
variables (Porter et al., 2008).
ANOVA tables were generated and P-values less 
than 0.05 were considered to be statistically significant. 
The polynomial equation was obtained for disintegration 
time and friability using Design Expert software. 
Y=b0+b1 X1+b2 X2
where Y is the dependent variable, b0 is the arithmetic 
mean response of the nine runs and bi(b1 and b2)is the 
approximate coefficient for the correlated factor Xi (X1 and 
X2). The validity of the developed polynomial equation 
was verified using design check point analysis.
Evaluation of NEB IR-SET
NEB IR SET tablets were evaluated for various 
parameters namely hardness,%friability, in vitro 
disintegration time, turbidity measurement and percent 
transmittance, Droplet size analysis and polydispersity 
index, zeta potential, drug content, dissolution studies and 
stability testing. Hardness of tablets (n=3) was estimated 
by Monsanto hardness tester. Friability was estimated 
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using Roche friabilator (Veego scientific, India). Tablets 
(n=6) from every batch were selected randomly, weighed 
and placed in the plastic chamber provided in apparatus. 
Friabilator was operated for 100 revolutions and tablets 
were collected, de-dusted and reweighed. Percent friability 
was determined by the difference obtained in two weights. 
The in vitro disintegration test was done in accordance 
with USP. The emulsion layer was separated as supernatant 
from adsorbed solid components present in tablets 
by centrifuging the medium containing disintegrated 
tablets at 1000 rpm for 3 min. The obtained emulsion 
was then further analyzed for droplet size and turbidity 
measurement. While the other parameters were evaluated 
by the same procedure as given under the evaluation of 
L-SMEDDS (Ahammad, Pani, 2016).
In-vitro drug release 
In-vitro drug dissolution study was performed for 
L-SMEDDS, IR-SET, Plain drug and Marketed tablets 
using USP dissolution apparatus II. Test conditions for 
dissolution were 900 mL of dissolution medium i.e. 
HCl buffer pH 1.2., with a rotating speed of 50 rpm and 
temperature 37±0.5 °C. During the study, 10 mL of the 
aliquots were removed at predetermined time intervals 
(10, 20, 30, 40, 50, and 60 minutes) from the dissolution 
medium and replaced with fresh medium. The amount of 
NEB released in the dissolution medium was determined 
spectrophotometrically (Rao et al., 2013).
Ex-vivo release profile
For ex-vivo study, stomach of previously sacrificed 
Male Sprague-Dawley rat was isolated and thoroughly 
washed with phosphate saline buffer pH 7.4 to remove 
the mucous and lumen contents. NEB loaded formulations 
(L-SMEDDS/IR-SET/Plain drug/Marketed tablets) were 
diluted/dispersed separately with HCl buffer pH 1.2 and 
filled in the stomach. Both the ends of the tissues were tied 
properly to avoid any leakage and were placed into beaker 
containing 50 mL of phosphate saline buffer pH 7.4 as the 
diffusion medium with the continuous aeration supply 
under gentle stirring at 37±2 °C. Samples were drawn from 
the medium at specific time intervals and were evaluated 
by spectrophotometric analysis (Vijayanand, Patil, Reddy, 
2015).
Stability study
A short term stability study of NEB L-SMEDDS 
and NEB IR-SET was performed for three months for 
which the glass vial was filled with optimized L-SMEDDS 
and placed in stability chambers at 40 °C /75% RH. 
Formulation was removed at each time point (0 day, 
1 month, 2 month and 3 month) and evaluated for self 
emulsification time, drug content and% drug release in 
10 minutes and percent friability (Kamble et al., 2012).
RESULTS AND DISCUSSION
Preformulation studies
The melting point range was found to be 228-230oC 
by Thiele tube method which met the criteria. The λmax 
of NEB was found to be 282 nm in methanol. Figure 1 
shows the regression equation and correlation coefficient 
for calibration in methanol, pH 1.2 HCl buffer and 
pH 7.4 PBS. The regression equation for all the solvents 
followed Lambert-Beer’s law and a linear relationship 
was depicted by the correlation coefficient which was 
found to be near 1.The linearity range was 20-100 μg/mL. 
The%RSD values for intra-day and inter-day validation 
parameters were found to be 0.6260 and 0.4210. While 
the% RSD values for robustness and ruggedness were 
found to be 0.2890 and 0.2732. The percent recovery for 
20, 30 and 40 μg/mL solutions were found to be 99.037, 
98.210, and 95.340% respectively. The Limit of Detection 
(LOD) and limit of quantification (LOQ) for 10 μg/mL 
was found to be 0.5202 and 0.0663 respectively. The 
validation study confirms adequate sample stability and 
method reliability over a period of 24 h as the selected 
concentration lies within linearity range and observed 
RSD was less than 2%. The FT-IR spectrum of NEB 
exhibited characteristic peaks (Figure 2A) while the 
DSC graph of NEB displayed a sharp endothermic 
peak at 233.3 °C corresponding to its melting point and 
indicating its crystalline nature(Figure 3A). 
Solubility studies - selection of L-SMEDDS 
components
Selection of oil 
The goal of the solubility study was to identify 
a suitable oily phase for the development of the NEB 
SMEDDS. The oil having the maximal solubilizing 
potential will be selected in order to achieve optimum 
drug loading (Prajapati, Joshi, Patel, 2013). The solubility 
values of NEB in various oils, surfactants and cosurfactants 
are given in Table II. Among the various oils that were 
screened, Kollisolv IPM and Kollisolv GTA showed 
maximum solubility because of their hydrophilic 
nature, as compared to others (12.41 ± 1.31 mg/mL & 
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FIGURE 1 - Calibration curve of NEB in (A) Methanol, (B) pH 1.2 HCl buffer, (c) Phosphate buffer pH 7.4.
FIGURE 2 - FTIR spectra of (A) Nebivolol HCl (B) L-SMEDDS (C) IR-SET.
7.98 ± 1.08 mg/mL respectively) (BASF, 2012, 2013). 
While the selection of the surfactant and cosurfactant in 
the further study was determined by their emulsification 
efficiency.
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Selection of surfactants
Nonionic surfactants are used for oral ingestion 
as they are considered less toxic that ionic surfactants 
(Porter et al., 2008). Thus based on solubility studies 
Kollisolv GTA, Kollisolv IPM, and Castor oil: Acrysol 
K 140 were selected as oil phases and Acrysol K 140, 
Acrysol EL 135, Tween 80 and Span 80 were selected as 
surfactants. The emulsification efficiency of surfactants 
was determined and the results are given in Table III. 
From the surfactant emulsification test, Kollisolv GTA 
showed good emulsification efficiency with all surfactants 
and highest% transmittance of about 99.613% with 
Tween 80.Whereas, Kollisolv IPM in spite of having 
highest solubility, its emulsification efficiency was poor 
and hence Kollisolv GTA & Tween 80 were selected as oil 
and surfactant, respectively for further studies. 
Selection of co-surfactant
Based on solubility studies, PEG 400, PEG 200 and 
Propylene Glycol were selected as co-surfactants. The 
emulsification efficiency with Kollisolv GTA as oil and 
Tween 80 as surfactant was performed and the results 
(Table IV) showed that Propylene glycol gave highest% 
transmittance of 99.57% because of being water soluble 
(Madan, Sudarshan, Kadam, 2014) and hence was selected 
as co-surfactant for further studies. 
Drug excipients compatibility studies
FTIR studies
The FT-IR spectrum of NEB exhibited a sharp peak 
FIGURE 3 - DSC thermograms of (A) Nebivolol HCl (B) L-SMEDDS (C) IR-SET.











Acrysol EL 135 10.76±1.09
Solutol HS 7.19±0.45





Iso propyl alcohol 0.98±0.03
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of OH group at 3194.12 cm-1. It showed aromatic C-H and 
C-C stretch at 2964.85 cm-1 and 1750.00 cm-1respectively. 
The principal IR absorption peaks of NEB were observed 
in the L-SMEDDS and IR-SET spectrums. The spectrums 
of L-SMEDDS and IR-SET showed non-significant 
changes in the absorption peak of OH stretching of NEB 
from 3194.12 cm-1 to 3381.21 cm-1 and 3379.29 cm-1 
respectively (Figure 2). These spectral observations 
thus indicated no interaction between the NEB and the 
excipients (Narkhede, Gujar, Gambhire, 2014).
DSC studies
NEB displayed a sharp endothermic peak at 
233.3 °C. The thermogram of L-SMMEDS exhibited 
a diffused peak instead of a sharp endothermic peak 
demonstrating that the drug might be in a molecularly 
dissolved state in L-SMEDDS (Figure 3).While Optimized 
IR-SET showed the disappearance of endothermic peak 
which indicates the presence of drug in molecularly 
dissolved state (Figure 3). Hence, it can be concluded that 
there is no interaction of drugs with excipients and they are 
compatible (Narkhede, Gujar, Gambhire, 2014). 
Pseudoternary phase diagram
Pseudo-ternary phase diagrams were formulated 
without NEB to determine the self emulsifying regions and 
obtain the concentration range of excipients for the micro-
emulsion region. A chain of SMEDDSs were prepared and 
visually observed for their self-emulsifying properties. 
The pseudo-ternary phase diagrams were constructed for 
each system using CHEMIX software shown in Figure 4. 
It was discovered that as the concentration of the surfactant 
with respect to co-surfactant increases in SMEDDS 
formulation, the spontaneity of the self-emulsification 
region decreases. The maximum micro emulsion zone 
was shown at the Smix ratio of 1:2 as compared to others. 
Hence, surfactant: co-surfactant ratio (1:2) was selected 
for the formulation. Moreover similar phase diagram 
was obtained when constructed in the presence of NEB 
(Figure 4F) (Khan et al., 2012).
Formulation and Optimization of NEB loaded 
L-SMEDDS by Experimental design
The 32 factorial design was constructed for the 
optimization of NEB loaded L-SMEDDS. The 9 
experimental runs with actual values of independent 
variables and observed response parameters i.e. Droplet size 
(Y1), Emulsification time (Y2) and Percent transmittance 
(Y3) are shown in Table V. Very wide variation is observed 
in the droplet size and self emulsification time and little 
variation in% transmittance on changing the composition 
of formulation. The droplet size, self emulsification time 
TABLE III - Emusification efficiency of oil with different surfactants
Oil Surfactant Appearance % Transmittance
Kollisolv IPM Acrysol K 140 Hazy bluish transparent 76.4553
Acrysol EL 135 Hazy + Milky 53.7765
Tween 80 Hazy bluish transparent 93.5831
Span 80 Hazy bluish transparent + precipitate 10.518
Kollisolv GTA Acrysol K 140 Clear transparent 99.1441
Acrysol EL 135 Clear transparent 98.6482
Tween 80 Clear transparent 99.6139
Span 80 Hazy bluish transparent + precipitate 77.348
Castor oil: Acrysol K 140 Acrysol K 140 Hazy bluish transparent 93.0874
Acrysol EL 135 Clear transparent 98.4155
Tween 80 Hazy bluish transparent 87.0026
Span 80 Hazy Milky 51.3911
TABLE IV - Emulsification efficiency of Kollisolv GTA -Tween 80 with different co-surfactants
Oil/Surfactant Co-surfactants Appearance % Transmittance
Kollisolv GTA/Tween 80 PEG 200 Clear transparent 98.1737
Kollisolv GTA/Tween 80 PEG 400 Clear transparent 98.9188
Kollisolv GTA/Tween80 Propylene glycol Clear transparent 99.5708
H. R. Trivedi, T. M. Siriah, P. K. Puranik
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and% transmittance ranged from 55.98 nm to 203.6 nm, 
16±1.52 s to 103±2.51 s, and 94.14±0.45 to 99.94±0.47, 
respectively (Table V). Batch F3 shows smallest droplet 
size (55.98 nm), minimum self emulsification time 
(16±1.52 s) and highest% transmittance (99.94%) and was 
selected for further processing.
Statistical analysis was carried out for all nine 
formulation batches by Design-Expert Software (Version 
8.0.7.1, Stat-EaseInc., Minneapolis, MN). The effect of 
independent variables can be explained based upon the 
following equations:
(Droplet size)Y1 = 120.22 + 39.38 X1 – 20.18 X2
(Emulsification time)Y2 = 54.56 + 26.17 X1 – 17.83 X2
(Percent transmittance)Y3 = 98.61 + 0.053X1 + 1.75 X2 – 
1.24 X1X2 + 0.41 X12 – 1.56 X22
Statistical significant coefficients (P=0.0165 and F 
value=8.79 for Y1, P=0.0170 and F value=8.66 for Y2 while 
for Y3 P=0.0294 and F value=13.27) were obtained for the 
model. From the P and F values, it could be concluded 
that the independent variables i.e. concentration of oil(X1) 
and concentration of Smix(X2) significantly affect the 
responses. The positive coefficient of X1& X2 indicates 
that the response is favored while the negative value 
indicates an inverse relationship between the factor and the 
response. The equations exhibit that as the concentration 
of oil(X1) increases droplet size and emulsification time 
increases while as concentration of Smix(X2) increases 
droplet size and emulsification time decreases. On the 
other hand both the factors have positive relationship on 
Percent transmittance (Y3) (Akhildevi et al., 2016). 
The check point formulation (NEB L-SMEDDS) 
was based on the optimum process variables and desired 
responses. The concentration of oil(X1) and concentration 
of Smix(X2) chosen were 200mg and 770mg respectively. 
The Droplet size (Y1), Emulsification time (Y2) and 
Percent transmittance (Y3), predicted and experimental 
results are summarized in Table VI. The predicted value 
was compared with experimental value by calculating 
percentage error (0.61%) which was found to be quite low, 
proved validity of generated model in predicting response.
The similarity between experimental and predicted values 
indicated the validity of the generated model. The contour 
plots and 3D response curves were obtained as shown in 
Figure 5. 3D figures showed linear ascending pattern for 
droplet size, emulsification time and percent transmittance 
with increasing concentration of Smix.
Evaluation of L-SMEDDS
Self emulsification time analysis and percent 
transmittance
Self emulsification time analysis is an important 
FIGURE 4 - Pseudo-ternary phase diagram of (A) Smix (1:1), (B) Smix (1:2), (C) Smix (1:3), (D) Smix (2:1), (E) Smix (3:1), 
(F) Smix(1:2) with drug.
Experimental design approach for development of novel microemulsion system
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TABLE V - Optimization of L-SMEDDS using Factorial design
Batches
X1 
Conc. of Oil 
(mg)
X2 











F1 200 400 117.57 29±2.08 94.14±0.45
F2 200 600 71.91 22±3.01 99.71±0.26
F3 200 800 55.98 16±1.52 99.94±0.47
F4 400 400 136.91 76±2.08 95.26±0.36
F5 400 600 91.6 92±2.00 98.32±0.41
F6 400 800 126.3 32±3.05 99.13±0.38
F7 600 400 203.6 103±2.51 97.32±0.21
F8 600 600 123.4 68±1.46 98.63±0.42
F9 600 800 154.71 53±2.42 98.16±0.33





Droplet size (nm) 60.6633 55.98
Emulsification time (sec) 10.5556 16±1.52
% Transmittance (%) 100.401 99.94±0.47
IR-SET 
(Batch B9)
Disintegration time (sec) 97.7222 92±0.57
Friability (%) 0.428944 0.424±0.03
parameter for determining the emulsification efficiency i.e. 
SMEDDS should quickly disperse under mild agitation. 
The self emulsification time for the optimized batch (F3) 
was 16±1.52 s and the percent transmittance at wavelength 
of 650 nm was found out to be 99.94±0.47% indicating 
low particle size.
Droplet size analysis and polydispersity index
The smaller droplet size of the micro emulsion 
indicates  more rapid absorpt ion and improved 
bioavailability of drug. Results displayed that as the 
concentration of Smix increases the mean droplet size 
decreases. The optimized formula (F3) showed 55.98 nm 
droplet size and 0.37 polydispersity index. Figure 6A 
depicts the distribution of droplet size in optimized formula. 
While the stability of the emulsion was determined by 
zeta potential as it directs the degree of repulsion between 
similarly charged, adjacent, dispersed droplets. The zeta 
potential value depending on a specific system being used, 
if reduced below a certain value leads to flocculation or 
instability (Bakhle, Avari, 2015).The zeta potential of 
the optimized formula (F3) was found to be -26.8 mV, 
indicating the stable micro emulsion (Figure 6C).
Drug loading capacity
Drug loading capacity of optimized batch (F3) 
containing Kollisolv GTA, Tween 80 and Propylene glycol 
was found to be 17.6420 ± 0.09 mg/g.
Cloud point determination
Cloud point is the temperature point at which 
there is a sudden impression of turbidity appearing in 
the formulation visually (Jaiswal et al., 2014). Hence 
this study assists in determining the performance of 
developed SMEDDS formulation at body temperature. 
Cloud point of optimized formula (F3) was found to 
be 85°C, which indicates that micro emulsion will be 
stable at physiological temperature without risk of phase 
separation.
Phase separation study
Dilution may better mimic conditions in the stom-
ach following oral administration of SMEDDS pre-
concentrate. Dilution study was done to determine the 
effect of dilution on SMEDDS pre-concentrates. After 
diluting SMEDDS to 50, 100 and 1000 times with water, 
acid buffer pH 1.2 and phosphate saline buffer pH 7.4 and 
H. R. Trivedi, T. M. Siriah, P. K. Puranik
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FIGURE 5 - Response surface plot for (A) Droplet size (B) Emulsification time (C) Percent transmittance.
FIGURE 6 - (A) Droplet size distribution of optimized L-SMEDDS, (B) Droplet size distribution of optimized IR-SET, (C) Zeta 
potential of optimized L-SMEDD, (D) Zeta potential of optimized IR-SET. 
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storing for 12 h, it was observed that there was no sign 
of phase separation or drug precipitation. This suggests 
that the formulation (F3) was robust to dilution and 
change in diluents, thus maintaining their performance 
in vivo.
Thermodynamic stability
Thermodynamic stability studies helps in detection 
of detrimental alterations in formulations occurred over 
a significant period of time. Thermodynamic stability 
study avoids any metastable SMEDDS formulations. This 
instability basically arises from surfactant concentration. 
However, the optimized formula (F3) displayed good 
stability to all the three phases (heating cooling cycle/ 
freeze thaw cycle) and showed no sign of precipitation 
or phase separation even after centrifugation and were 
subjected for further characterization.
Drug content
There is a direct relationship between the drug 
incorporated and the lipophilicity of the drugs. Drug with 
higher lipophilicity can be encapsulated more than the 
other drugs. Drug content of L-SMEDDS was found to 
be 4.87 ± 0.05 mg/mL. So, drug content in percentage 
was calculated and the optimized formula (F3) had 
97.43 ± 0.30% of drug.
Preparation of Solid NEB SMEDDS
A free f lowing powder was formulated by 
solidification of the optimized L-SMEDDS formulation 
(F3) by adsorption onto the selected carrier in particular 
ratio.
Selection of adsorbent for S-SMEDDS 
The S-SMEDDS of individual adsorbent like 
Neusilin US2, Aerosil 200, microcrystalline cellulose 
PH102 and Lactose were prepared by adsorption onto 
the carrier technique. The angle of repose and quantity of 
adsorbent required was observed as a response. Among the 
different adsorbents (Table VIII), Neusilin US2 showed 
good flow property in ratio of 1:0.5 whereas Aerosil 200 
was also required in same ratio but shown passable flow 
property. This can be explained by the fact that Neusilin 
US2 has a large specific area with high oil and water 
adsorption capacity (Qureshi, Mallikarjun, Kian, 2015) 
and therefore was selected as adsorbent. 
Evaluation of S-SMEDDS 
The S-SMEDDS prepared from optimized 
L-SMEDDS and Neusilin US2 were evaluated further 
for flow properties, SEM and XRD studies. The flow 
of S-SMEDDS was found to be good with 32.72±2.4 
angle of repose, 13.48±0.6 carrs index and 1.15±0.02 
of hausners ratio. SEM micrograph of NEB (Figure 7A) 
showed smooth rectangular crystalline structures. 
While that of Neusilin US2 (Figure 7B) appeared to 
be spherical porous particles. Micrograph of solid 
SMEDDS (Figure 7C) showed liquid SMEDDS adsorbed 
onto the surface of Neusilin US2 particles. Crystalline 
characteristic structures of solid NEB were not detected 
in solid SMEDDS micrographs indicating that the drug 
must be present in an entirely dissolved state in the 
solid SMEDDS. X ray diffraction (XRD) study was 
performed to recognize various polymorphic forms of 
TABLE VII - Stability studies of L-SMEDDS & IR-SET
Formulation Time Period (days)
Storage condition (40 °C/ 75% RH)
Emulsification time 
(sec) Drug content (%)
% Cumulative drug 
release in 10 min 
L-SMEDDS 
(Batch F3)
0 16±1.52 97.43±0.30 73.44±1.14
30 23±2.08 96.81±0.30 68.56±2.45
60 20±1.73 96.59±0.47 70.5±1.76
90 17±2.12 95.3±0.72 72.83±1.99
Time Period (days) Friability (%) Drug content (%) % Cumulative drug release in 10 min
IR-SET 
(Batch B9)
0 0.424±0.03 96.33±0.15 61.28±2.39
30 0.469±0.02 96.56±0.2 57.07±1.8
60 0.411±0.03 95.83±0.4 56.79±2.07
90 0.439±0.05 95.48±0.19 55.89±1.4
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the formulation and to detect the solvated and unsolvated 
state of the formulation. X-Ray diffraction studies of NEB 
(Figure 8A) showed sharp, distinct peaks at 5.9º, 11.9º, 
12.2º, 16.3º, 18.4º, 21.4º, 22.4º, and 25.67º confirming 
that the pure drug is in the crystalline state. Whereas XRD 
graph of S-SMEDDS (Figure 8B) showed absence of NEB 
constructive peaks indicating conversion of NEB from 
crystalline to amorphous state in optimized formulation 
mainly because of solubilisation in the SMEDDS which 
was further adsorbed on to the solid carrier Neusilin US2 
(Bakhle, Avari, 2015).
TABLE VIII - Adsorbent selection for S-SMEDDS
Adsorbent Adsorbent required(ratio) Angle of Repose
Aerosil 200 1:0.5 41.81±1.18 (passable)
Neusilin US2 1:0.5 32.72±2.4(good)
MCC PH102 1:2 43.15± 1.55 (passable)
Lactose 1:1.5 37.32± 2.17 (fair)
FIGURE 7 - SEM images of (A) Nebivolol HCl (B) Neusilin US2 (C) S-SMEDDS.
FIGURE 8 - XRD graph of (A) Nebivolol HCl (B) S-SMEDDS
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Formulation of immediate release self emulsifying 
tablet (IR-SET)
Selection of super-disintegrant
The criteria for selection of superdisintegrant 
depended on the minimum time required for disintegration. 
KOLLIDON CL showed minimum disintegration time of 
245 s. While Sodium starch glycollate and crosscarmellose 
sodium showed a disintegration time of about 419 and 
367 s respectively. This could be attributed to the fact 
that KOLLIDON CL swells without any gel formation or 
crosslinking and thus was selected for IR SET preparation. 
In this study, the combined effect of binder (PVP K30) 
as well as super disintegrant (KOLLIDON CL) on the 
disintegration time, friability and hardness was determined. 
PVP K30 has a shorter wetting time because of its small 
particle size, moreover the uneven surface increases the area 
subjected to disintegration media which leads to a decrease 
in disintegration time (Hadel, 2014). While KOLLIDON 
CL improves tablet disintegration through its low particle 
size, which enhances tablet hardness with reduced friability 
(Maschke, Bang, Kolter, 2008). Also the efficacy of 
super disintegrant is very much affected by tablet size 
and hardness. Larger and harder tablets will have greater 
disintegration time, moreover lower values in hardness may 
cause increased friability which will affect the robustness 
of the tablet. Therefore, to ensure low disintegration time 
and friability, a satisfactory and optimal amount of the 
disintegrant and binder is important. 
Formulation and optimization of NEB IR-SET using 
experimental design
The 32 factorial design was constructed to optimize 
NEB IR-SET. The 9 experimental runs with actual 
values of independent variables and observed response 
parameters i.e. Disintegration time (Y1) and Friability 
(Y2) are given in Table IX. The optimized formula of 
NEB IR-SET contained L-SMEDDS loaded Neusilin 
US2 equivalent to 5mg of drug concentration with 5% 
of PVP K30 and KOLLIDON CL and 1% magnesium 
stearate respectively. Very wide variation is observed 
in disintegration time and friability on changing the 
composition of formulation. The disintegration time 
and% friability ranged from 92 ± 0.57 s to 169 ± 1.15 s 
and 0.424±0.03% to 0.783 ± 0.05%, respectively (Table 
IX). Batch B9 shows minimum disintegration time 
(92 ± 0.57 s) and minimum friability (0.424±0.03%) and 
thus was selected for further processing. 
Statistical analysis was carried out for all nine 
formulation batches by Design-Expert Software (Version 
8.0.7.1, Stat-EaseInc., Minneapolis, MN). The effect of 
independent variables can be explained based upon the 
following equations:
(Disintegration time)Y1= 128.56-0.67 X1-30.17 X2
(Friability)Y2= 0.59- 0.15 X1-9.167E-003X2
Statistical significant coefficients (P=0.0034 and F 
value=16.87 for Y1 and P=0.0019 and F value= 21.13 for 
Y2) were obtained for the model. From the P and F values, 
it could be concluded that the independent variables i.e. 
concentration of PVP K30 (X1) and concentration of 
KOLLIDON CL (X2) significantly affect the responses. 
The equations exhibit that as the concentration of 
PVP K30(X1) and KOLLIDON CL (X2) increases, 
disintegration time (Y1) and% friability values (Y2) 
decreases. 
The check point formulation (NEB IR-SET) was 
based on the optimum process variables and desired 
responses. The concentration of PVP K30(X1) and 
KOLLIDON CL (X2) chosen were 5% and 4.75% 
respectively. The disintegration time (Y1) and friability 
(Y2), predicted and experimental results are summarized 
in Table VI. The predicted value was equated with 
experimental value by calculating percentage error 
(0.52%) which was found to be quite low, proved validity 
of generated model in predicting response. No significant 
difference was recorded between these two values, hence 
affirming the validity of generated model. 3D figures 
showed linear descending pattern for disintegration time 
and friability with increasing concentration of PVP K30 
and KOLLIDON CL (Akhildevi et al., 2016) (Figure 9). 
Evaluation of NEB IR-SET
The optimized IR-SETS (B9) were subjected to 
friability testing using Roche Friabilator and showed 
0.424 ± 0.03% friability. The friability is less than 1%, 
which indicates that the tablets can handle the mechanical 
stress. Hardness was measured using Monsanto hardness 
tester which showed acceptable hardness in the range 
2.5 ± 0.11 kg/cm2 to 2.8 ± 0.29 kg/cm2 indicating that the 
tablets can handle the mechanical stress (USP 36, 2013). 
While the hardness of the optimized batch (B9) was found 
to be 2.8 ± 0.29 kg/cm2. Disintegration time for nine batches 
ranged from 92 ± 0.57 s to 169 ± 1.15 s with disintegrating 
time of 92 ± 0.57 s for batch B9, exhibiting that the tablet 
can disintegrate and release the self emulsifying system 
immediately. The low hardness values can be attributed 
to the fact that PVP K30 forms large number of pores in 
compressed tablet (Tuntikulwattana et al., 2010) on the 
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TABLE IX - Optimization of IR-SET using Factorial design
Batches X1 Conc. of PVP K30 (%)
X2 





B1 2.00 5.00 112±1.52 0.783±0.05
B2 2.00 2.00 156±2.08 0.756±0.03
B3 2.00 3.50 125±0.57 0.735±0.04
B4 3.50 5.00 101±1.15 0.532±0.07
B5 3.50 3.50 105±0.57 0.558±0.05
B6 3.50 2.00 169±1.15 0.515±0.05
B7 5.00 2.00 161±0.57 0.523±0.03
B8 5.00 3.50 136±1.52 0.443±0.04
B9 5.00 5.00 92±0.57 0.424±0.03
FIGURE 9 - Response surface plot for (A) Disintegration time (B) Friability.
other hand greater number of pores cause more water 
penetration thus leading to quick disintegration of tablets 
(Sharma, 2013; Hadel, 2014). The optimized IR-SETS 
after dilution showed clear appearance indicating single 
phase and the percent transmittance at wavelength of 
650 nm was found out to be 98.67 ± 0.73%. Smaller the 
size of microemulsion droplet faster is the absorption. The 
optimized IR-SET showed 68.57 nm droplet size and 0.34 
polydispersity index. Figure 6B shows the droplet size 
distribution of optimized formula. The zeta potential of 
optimized IR-SET was found to be -25.3 mV, depicting 
the stable micro emulsion (Figure 6D).Drug content of 
optimized IR-SETS was found to be 4.81 ± 0.03 mg/mL 
and percentage of drug content was calculated which had 
96.33 ± 0.15% of drug.
In-vitro drug release
The in vitro dissolution studies were carried out in 
order to ensure the quick release of the drug in the medium. 
The in vitro dissolution of the L-SMEDDS, IR-SET, 
Plain drug and Marketed tablets were performed in 900 
mL of acid buffer pH 1.2 using USP Type II dissolution 
apparatus with a paddle speed of 50 rpm. For L-SMEDDS 
and IR-SET formulations (Table X), it was observed that 
73.44% and 61.28% of the drug released within first ten 
minutes of the dissolution time, respectively. This indicates 
that conversion of L-SMEDDS to IR-SET does not affect 
the drug release much more.Whereas, Plain drug and 
Marketed tablets, showed only 13.79% and 17.10% of the 
drug release, respectively. This clearly demonstrates the 
superior dissolution behavior of the developed SMEDDS as 
compared to Plain drug and Marketed tablets (Figure 10A). 
From the mathematical treatment of the in vitro release 
data of NEB from L-SMEDDS, IR-SET, Plain drug and 
Marketed tablet, the values of R2 (regression coefficient) 
has been obtained and presented in Table XI. From the 
regression coefficient value it was observed that drug release 
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follows first order kinetics in L-SMEDDS and IR-SET 
systems while it followed higuchi model in Plain drug and 
Marketed tablet drug release. The data was further treated as 
per Korsmeyer’s equation and slope (n) values obtained by 
these equations indicated that the drug release mechanism 
was Fickian diffusion in L-SMEDDS and IR-SET systems 
while it was Non-Fickian diffusion for Plain drug and 
Marketed tablet (Rao et al., 2013).
Ex-vivo release profile
Ex vivo studies were performed in order to determine 
the diffusion through biological membrane. After 2 h of 
diffusion, L-SMEDDS showed 97.56% of drug diffusion 
and IR-SET gave 93.24% of drug diffusion, while the 
dispersion of Plain drug and Marketed tablet gave 64.28% 
and 72.73% of drug diffusion respectively (Table XII). 
This indicates that diffusion of drug through the biological 
TABLE X - In-vitro drug release profile 
Time (min)
% Cumulative drug release
L-SMEDDS IR-SET Plain drug Marketed tablet
0 0±0 0±0 0±0 0±0
10 73.44±1.14 61.28±2.39 13.79±1.39 17.10±1.10
20 82.92±4.66 74.65±2.99 18.65±2.86 21.20±1.27
30 92.93±3.14 79.43±3.57 21.84±1.64 29.14±1.61
40 95.20±2.41 86.48±1.24 26.71±2.62 33.73±1.28
50 98.42±3.75 91.33±2.39 28.71±3.93 43.91±3.91
60 98.97±3.63 96.19±4.99 30.53±2.87 44.62±2.98
70 - 96.89±4.05 32.46±1.81 46.35±1.63
80 - 98.51±4.87 35.56±2.87 47.78±2.56
90 - 98.38±4.80 39.58±4.59 48.85±2.31
FIGURE 10 - In-vitro drug release profile and Ex-vivo diffusion studies of the L-SMEDDS, S-SMEDDS, Plain drug and Marketed 
formulation.
membrane was more when given in the form of SMEDDS 
formulations (Figure 10B). The augmentation in diffusion 
rate is due to formation of small droplets in nanometer 
range which enhanced the permeation of NEB because of 
the surfactant present, which reduced the interfacial tension 
within the formulation (Vijayanand, Patil, Reddy, 2015).
Stability study
Stability study results of the optimized batch 
L-SMEDDS (F3) and IR-SET(B9) are given in Table VII 
showing no significant changes during the study period of 
three months which further indicates that the formation is 
stable on storage (Kamble et al., 2012).
CONCLUSION
Self microemulsifying delivery system of NEB HCl 
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TABLE XI - Drug release kinetics
Formulation code
Zero order First order Higuchi model Korsmeyer- Peppas model
R2 R2 R2 R2 N
L-SMEDDS 0.870 0.984 0.937 0.971 0.175
IR-SET 

















TABLE XII - Ex-vivo diffusion studies
Time (min)
% Cumulative drug release
L-SMEDDS IR-SETS Plain drug Marketed tablet
0 0 0 0 0
15 18.95 10.38 9.48 9.98
30 25.39 17.77 15.14 15.45
45 42.34 25.71 26.57 30.35
60 60.18 41.53 33.20 38.20
75 79.53 56.24 45.48 50.22
90 92.06 68.60 58.64 61.48
105 93.88 79.31 60.23 67.36
120 97.56 93.24 64.28 72.73
were successfully designed, formulated and optimized 
as L-SMEDDS and IR-SET using experimental design. 
Optimized L-SMEDDS contains Kollisolv GTA as 
oil, Tween 80 as surfactant and Propylene glycol as 
cosurfactant in the ratio of 20%:26.66%:53.34% w/w 
which gave lower droplet size (55.98 nm), PDI (0.37), 
emulsification time (16 ± 1.52 s), zeta potential (-26.8 mV) 
and drug content (97.43±0.30%). The optimized 
L-SMEDDS, batch F3 were successfully converted into 
a free flowing powder(S-SMEDDS) using Neusilin US2 
which was directly compressed into self emulsifying 
immediate release tablets (IR-SET). DSC and XRD data of 
the solid SMEDDS powder established that the drug was 
completely solubilized in the lipid excipients and /or the 
crystalline form of the drug was converted to molecular/
amorphous one. Optimized IR-SETS contains PVP K30 
as binder, KOLLIDON CL as super disintegrant in the 
ratio 5%:5% and showed disintegration time (92 ± 0.57 s), 
friability (0.424 ± 0.03%), hardness (2.8 ± 0.29 kg/
cm2), droplet size (68.57 nm), PDI (0.34), zeta potential 
(-25.3 mV) and drug content (96.33 ± 0.15%).Also 
the in vitro dissolution performance was similar for 
L-SMEDDS and IR-SET showing 73.44% and 61.28% 
drug release in 10 minutes, respectively which was 
significantly higher than the marketed tablet and plain 
drug. Stability studies showed absence of chemical and 
physical changes over a period of 90 days. Thus NEB can 
be successfully designed and formulated as L-SMEDDS 
and subsequently into S-SMEDDS (IR-SET) with 
drastically improved release characteristics.
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